Methods of use of anti-CD37 antibodies, monoclonal anti-CD37 antibodies

A method of treating an autoimmune disease or inflammatory disease characterized by CD37 expression, the method comprising administering to an individual in need thereof a therapeutically effective amount of an antibody which binds to human CD37, wherein the antibody comprises:

• (i) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
• 16, 17, and 18, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO:
• 20, KAS, and SEQ ID NO:
• 21, respectively;
• (ii) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
• 9, 10, and 11, respectively, and a variable light chain (VL) region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO:
• 13, AAS, and SEQ ID NO:
• 14, respectively;
• (iii) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
• 23, 24, and 25, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO:
• 27, YAS, and SEQ ID NO:
• 28, respectively;
• (iv) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
• 23, 24, and 25, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO:
• 27, YAS, and SEQ ID NO:
• 31, respectively;
• or
• (v) a VH region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:
• 2, 3, and 4, respectively, and a VL region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NO:
• 6, EAS, and SEQ ID NO:
• 7, respectively;
• wherein the antibody of any one of (i)-(v) optionally comprises an Fc region comprising at least one amino acid substitution selected from the group consisting of:
• E430G, E345K, E430S, E430F, E430T, E345Q, E345R, E345Y, S440Y and S440W;
• and
• wherein optionally the Fc region further comprises a K409R or F405L mutation.